Vivace secures $35m in Series D for cancer drug development

Vivace Therapeutics has successfully raised $35 million in a Series D funding round, earmarked for the advancement of its innovative cancer drug, VT3989. This drug is designed to inhibit TEAD autopalmitoylation, targeting the Hippo pathway, which plays a crucial role in the development of cancer. The financing was led by RA Capital Management, with significant contributions from existing investors Cenova Capital and Canaan Partners. These funds will primarily support the clinical development of VT3989, with a particular emphasis on treating mesothelioma, a challenging cancer type often linked to asbestos exposure.

VT3989 has already undergone evaluation in an ongoing open-label Phase I clinical trial involving 150 participants. This multicentre study aims to investigate the drug’s biological efficacy, safety profile, tolerability, and pharmacokinetics. Subjects in the trial include those with refractory metastatic solid tumors, notably refractory pleural malignant mesothelioma. The interim results have been encouraging, especially for patients who have not benefited from standard chemotherapy or combined immuno-oncology treatments.

Building on these promising outcomes, Vivace Therapeutics is preparing to transition VT3989 into a registrational Phase III trial. The company plans to engage with the US Food and Drug Administration (FDA) in the latter half of 2025 to discuss the drug's development pathway and seek alignment on regulatory requirements for the upcoming trial phase.

The leadership at Vivace Therapeutics is optimistic about the future of VT3989. CEO and President Sofie Qiao expressed confidence in the drug’s potential impact, stating that the clinical data acquired thus far supports advancing to a Phase III trial for mesothelioma patients. The company is committed to executing its strategic plan, which includes finalizing the current clinical trial and coordinating with the FDA to ensure a smooth transition to subsequent phases.

In addition to the financial boost, the company announced a strategic enhancement to its governance structure. Jake Simpson, a partner at RA Capital Management, has joined Vivace Therapeutics' board of directors. This move is anticipated to bring additional expertise and guidance as the company navigates the complex landscape of cancer drug development.

Overall, the successful funding round and the strategic planning for VT3989 mark significant milestones for Vivace Therapeutics. As the company gears up for the next phases of its drug development program, it remains steadfast in its mission to address unmet needs in cancer treatment, particularly for mesothelioma patients who have limited options after traditional therapies fail. With the anticipated collaboration with the FDA and the continued support from its investors, Vivace Therapeutics is poised to make substantial strides in the fight against cancer.